Microfluidic-based capture and release of cancer-derived exosomes via peptide–nanowire hybrid interface. Issue 3 (24th December 2020)

• Record Type: Journal Article
• Authors: Suwatthanarak, Thanawat; Thiodorus, Ivan Adiyasa; Tanaka, Masayoshi; Shimada, Taisuke; Takeshita, Daiki; Yasui, Takao; Baba, Yoshinobu; Okochi, Mina
• Is Part Of: Lab on a chip. Volume 21:Issue 3(2021)
• Page Start: 597
• Page End: 607
• Publication Date: 2020-12-24
• Subjects: Miniature electronic equipment -- Periodicals; Combinatorial chemistry -- Periodicals; Biotechnology -- Periodicals; 543.0813
• DOI: 10.1039/d0lc00899k
• Languages: English
• ISSNs: 1473-0197

Abstract

Abstract : A peptide–nanowire interface that can effectively capture cancer-derived exosomes and release captured intact exosomes was constructed. Abstract : Cancer-derived circulating exosomes or nanoscale extracellular vesicles are emerging biomarkers for disease detection and treatment because of their cell-specific constituents and unique intercellular pathways. For efficient exosome isolation from bio-fluids, the design of high-affinity nanointerfaces is of great importance in the development of miniaturized systems for the collection of exosomes. Herein, we report peptide-functionalized nanowires as a biorecognition interface for the capture and release of cancer-derived exosomes within a microfluidic channel. Based on the amino-acid sequence of EWI-2 protein, a partial peptide that bound to the CD9 exosome marker and thus targeted cancer exosomes was screened. Linkage of the exosome-targeting peptide with a ZnO-binding sequence allowed one-step and reagent-free peptide modification of the ZnO nanowire array. As a result of peptide functionalization, the exosome-capturing ability of ZnO nanowires was significantly improved. Furthermore, the captured exosomes could be subsequently released from the nanowires under a neutral salt condition for downstream applications. This engineered surface that enhances the nanowires' efficiency in selective and controllable collection of cancer-derived exosomes provides an alternative foundation for developing microfluidic platforms for exosome-based diagnostics and therapeutics.